Rapid emergence of protease inhibitor resistance in hepatitis C virus.
About 170 million people worldwide are infected with hepatitis C virus (HCV). The current standard therapy leads to sustained viral elimination in only approximately 50% of the treated patients. Telaprevir, an HCV protease inhibitor, has substantial antiviral activity in patients with chronic HCV infection. However, in clinical trials, drug-resistant variants emerge at frequencies of 5 to 20% of the total virus population as early as the second day after the beginning of treatment. Here, using probabilistic and viral dynamic models, we show that such rapid emergence of drug resistance is expected. We calculate that all possible single- and double-mutant viruses preexist before treatment and that one additional mutation is expected to arise during therapy. Examining data from a clinical trial of telaprevir therapy for HCV infection in detail, we show that our model fits the observed dynamics of both drug-sensitive and drug-resistant viruses and argue that therapy with only direct antivirals will require drug combinations that have a genetic barrier of four or more mutations.
Rong
Libin
L
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Dahari
Harel
H
Ribeiro
Ruy M
RM
Perelson
Alan S
AS
D000998:Antiviral Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D016679:Genome, Viral; D016174:Hepacivirus / Q000201:enzymology*; D022781:Hepatocytes / Q000187:drug effects / Q000821:virology; D006801:Humans; D020128:Inhibitory Concentration 50; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D009154:Mutation; D009842:Oligopeptides / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011480:Protease Inhibitors / Q000494:pharmacology*; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009842:Oligopeptides; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C486464:telaprevir; C100416:peginterferon alfa-2a
Gastroenterology. 2006 Oct;131(4):997-1002
17030169
J Virol. 2009 Jun;83(11):5760-4
19321623
Gastroenterology. 2009 Oct;137(4):1448-58
19632233
J Biol Chem. 2007 Aug 3;282(31):22619-28
17556358
N Engl J Med. 2009 Apr 30;360(18):1827-38
19403902
J Virol. 1994 Mar;68(3):1660-6
7509000
Hepatology. 2009 Dec;50(6):1709-18
19787809
Nat Rev Genet. 2008 Apr;9(4):267-76
18319742
Nat Rev Drug Discov. 2007 Dec;6(12):991-1000
18049473
Hepatology. 1999 Jun;29(6):1863-9
10347131
AIDS. 1997;11 Suppl A:S17-24
9451962
Nature. 2004 Dec 16;432(7019):922-4
15602565
Gastroenterology. 2007 May;132(5):1767-77
17484874
Lancet. 1999 Nov 20;354(9192):1782-5
10577640
Antimicrob Agents Chemother. 2008 Jan;52(1):110-20
17938182
J Antimicrob Chemother. 2008 Jul;62(1):1-4
18441341
Nature. 2009 Sep 17;461(7262):399-401
19684573
Antiviral Res. 2007 Jan;73(1):78-83
16945431
Antimicrob Agents Chemother. 2009 May;53(5):2129-32
19273674
Hepatology. 2008 Dec;48(6):1769-78
19026009
Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20
16495264
AIDS. 1998 Mar 26;12(5):461-5
9543443
N Engl J Med. 2009 Apr 30;360(18):1839-50
19403903
Hepatology. 2007 Sep;46(3):640-8
17879366
N Engl J Med. 1998 Jul 9;339(2):61-8
9654535
Antimicrob Agents Chemother. 2008 May;52(5):1604-12
18285474
Antivir Ther. 2009;14(4):591-5
19578245
J Clin Virol. 2010 Jan;47(1):76-8
19857995
Lancet. 2001 Sep 22;358(9286):958-65
11583749
N Engl J Med. 1999 May 27;340(21):1605-13
10341272
Gastroenterology. 2007 May;132(5):1979-98
17484890
Immunol Cell Biol. 2002 Feb;80(1):36-44
11869361
J Mol Diagn. 2005 Oct;7(4):535-43
16237224
Nature. 2005 Aug 18;436(7053):953-60
16107835
Antimicrob Agents Chemother. 2006 May;50(5):1813-22
16641454
J Viral Hepat. 2009 Jun;16(6):377-87
19472445
Nature. 1997 May 8;387(6629):188-91
9144290
J Virol. 1996 Nov;70(11):7894-9
8892912
Nature. 2009 Oct 8;461(7265):798-801
19759533
Semin Liver Dis. 2003;23 Suppl 1:13-8
12934163
J Biol Chem. 2003 May 30;278(22):20374-80
12646587
Nature. 2003 Nov 13;426(6963):186-9
14578911
J Virol. 2009 Jul;83(13):6383-90
19369346
Hepatology. 2008 Aug;48(2):398-406
18553458
Nat Med. 1999 May;5(5):512-7
10229227
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398-402
8633078
Science. 1998 Oct 2;282(5386):103-7
9756471
Hepatology. 2007 Sep;46(3):631-9
17680654
Gastroenterology. 2007 Apr;132(4):1270-8
17408662
J Infect Dis. 1995 Jun;171(6):1411-9
7539472
Arch Intern Med. 1961 Mar;107:335-43
13764742
Aliment Pharmacol Ther. 2009 Apr 1;29(7):689-705
19183149
Nature. 2005 Aug 18;436(7053):933-8
16107832